Solitary lung metastasis from primary prostate cancer with normal prostate specific antigen levels: A case report and literature review

NATSUMI MARU ¹, ASAKO OKABE ², HARUAKI HINO ¹, TAKAHIRO UTSUMI ¹, HIROSHI MATSUI ¹, YOHEI TANIGUCHI ¹, TOMOHITO SAITO ¹, KOJI TSUTA ² and TOMOHIRO MURAKAWA ¹

Departments of ¹Thoracic Surgery and ²Pathology and Laboratory Medicine, Kansai Medical University Hospital, Hirakata, Osaka 573-1191, Japan

Received October 27, 2021; Accepted December 7, 2021

DOI: 10.3892/wasj.2021.139

Abstract. Pulmonary involvement from prostate cancer is a well-known condition; however, solitary lung metastasis is rare, with its associated clinical characteristics not yet fully elucidated. The present study describes the case of a 77-year-old male, who had undergone radical prostatectomy at a previous hospital for primary prostatic carcinoma 14 years prior, who presented with a low-grade fever. At the previous hospital, salvage radiation therapy was being considered, as the prostate-specific antigen (PSA) level had gradually increased within the normal range. Computed tomography performed at the authors' institution revealed a solitary nodule with a spiculated morphology located on the upper lobe of the left lung, while positron emission tomography suggested malignancy without metastasis. Based on these findings, primary lung cancer was suspected and thoracoscopic left upper lobectomy with lymph node dissection was performed. The pathological diagnosis of the tumor was a solitary lung metastasis of prostate cancer. The post-operative recovery was uneventful.

In addition to reporting a case with normal PSA levels, the present study also performed a literature review. According to previous case reports, there are some pitfalls of prostate cancer leading to misdiagnosis as a primary lung tumor. However, it is considered that surgical resection is associated with an increased diagnostic accuracy and long-term survival.

Introduction

Pulmonary metastasis secondary to prostate cancer has been reported in >40% of patients in an autopsy series (1). By contrast, solitary lung metastasis from prostate cancer is rare, and only 34 cases have been reported to date (Table I) (2-25). More than half of the patients (22/34) underwent lung resection, and the majority achieved cancer control and long-term survival.

The present study reports the 35th rare case of isolated lung metastasis from prostate cancer with normal prostate-specific antigen (PSA) levels 14 years after radical prostatectomy. In addition, a review of former case series was performed.

Correspondence to: Dr Natsumi Maru, Department of Thoracic Surgery, Kansai Medical University Hospital, 2-3-1 Shin-machi, Hirakata, Osaka 573-1191, Japan
E-mail: marunat@hirakata.kmu.ac.jp

Key words: solitary lung metastasis, lung metastasectomy, prostate cancer
<5.0 ng/ml); neuron-specific enolase, 8.2 ng/ml (<16.3 ng/ml); and pro-gastrin-releasing peptide, 50.9 pg/ml (<81.0 pg/ml). A thoracoscopic left upper lobectomy with hilar and mediastinal lymph node dissection was performed as a radical surgery for primary lung cancer. The duration of the surgery was 161 min and blood loss was 106 ml. An intraoperative frozen section was not submitted for examination due to the high index of suspicion for primary lung cancer based on the preoperative imaging and serum PSA levels within the normal range, and the limitations brought about by the coronavirus disease 2019 pandemic.

A post-operative histological examination revealed adenocarcinoma. The tumor exhibited crowded small glands with an amphophilic cytoplasm and enlarged nuclei with visible nucleoli (Fig. 2A and C). Immunohistochemical staining was then performed using sections at a thickness of 3-4 µm. The primary antibodies used were the following: Anti-thyroid transcription factor-1 monoclonal mouse antibody (clone 8G7G3/1; cat. no. 1R056; Dako; Agilent Technologies, Inc.), hepatocyte nuclear factor 4α monoclonal mouse antibody (clone H1415; cat. no. PP-H1415-00, Perseus Proteomics, Inc.), anti-human α-methylacyl-CoA racemase monoclonal rabbit antibody (clone 13H4; cat. no. M361629-2, Dako; Agilent Technologies, Inc.). The secondary reaction was performed using a Ventana OptiView DAB universal kit (111427; Roche Diagnostics K.K.). Antibody incubations were performed at 72°C for 16 min. No counterstain was used. The sections were examined under an Olympus BX51 microscope (Olympus Corporation). Immunohistochemical staining revealed thyroid transcription factor 1 (−), hepatocyte nuclear factor 4α (−), PSA (+) and α-methylacyl-CoA racemase (+) in the tumor cells (Fig. 2B and D). The tumor was diagnosed as differentiated adenocarcinoma metastatic from prostate cancer, based on hematoxylin and eosin staining and immunohistochemistry. Following surgery, the patient's recovery remained uneventful, and he was discharged on post-operative day 9. His serum PSA levels decreased to 0.07 ng/ml. He was closely followed-up at the Department of Urology in Kansai Medical University Hospital for 1 year and 4 months without any additional post-operative treatment. No recurrent signs, including an elevation in PSA levels, have been detected thus far.

Discussion

Prostate cancer has a high risk of biochemical recurrence, with the incidence ranging from 27 to 53% (26). It has been demonstrated that the mean interval between biochemical recurrence (PSA re-elevation >0.2 ng/ml twice following radical prostatectomy) and clinical recurrence (macroscopic appearance of the recurrent lesion that can be identified by imaging or histological examination) is ~8 years, suggesting that the long-term observation is required for patients with prostate cancer (27). For the patient presented herein, the possibility of a clinical recurrence should have been suspected when the CT scan revealed a lung nodule, as biochemical recurrence following radical prostatectomy was already observed in the previous 3 years. However, it was not suspected due to the following reasons: The CT findings of this case included a solitary lesion with a spiculated morphology, which is more typical of primary lung cancer, rather than a metastatic lung tumor, and the serum PSA level was still within the normal range. Additionally, solitary lung metastasis from prostate cancer is extremely rare. Previously, radiological evidence of pulmonary metastases following surgery, chemotherapy, or radiotherapy for prostate cancer was detected in 48 out of 1,290 patients (3.6%) while a solitary pulmonary nodule was detected in only 11 out of 1,290 patients (0.85%) (3). For these reasons, the clinical recurrence of prostate cancer was not strongly suspected preoperatively in the present case.

A search of PubMed and Ichuushi-web (http://www.jamas.or.jp) identified 24 articles and 34 patients with solitary lung metastasis from prostate cancer. A total of 22 articles described their cases in detail. The clinical characteristics of 23 cases were reviewed, including 22 from the literature and the present case (Table I). A review of a previous case series (4-25) helped to identify pitfalls which are prone to misinterpretation errors with significant consequences for patients.

First, the concept of the biochemical recurrence of prostate cancer is not a commonly known issue in the fields of surgery other than urology. However, considering the possibility of clinical recurrence from serum PSA fluctuations, even in patients with normal values as in the case presented herein, is crucial. It has been demonstrated that metastases from prostate cancer with normal serum PSA levels suggest high-grade cancer (GS≥8), small cell carcinoma, neuroendocrine tumor, or neuroendocrine differentiation (28). Among the prior 23 cases, high-grade cancer or neuroendocrine differentiation was found in 9 patients, and in the majority of cases (8/9), the serum PSA levels were within the normal range. However, even among patients with low-grade cancer, normal serum PSA levels were found in more than half of the cases (6/10). Of all the cases, 74% (17/23) had isolated lung metastasis with normal PSA levels, regardless of the histology.

The standard procedure for pulmonary metastases is partial resection aimed at the preservation of lung parenchyma. Among the reviewed 23 cases with solitary lung metastasis, 22 patients had undergone lung resection and 14 of them reported satisfactory outcomes. Lobectomy was performed in 9 patients, including the present case. The reasons for this procedure in some cases are highly suggestive. In four cases, intraoperative frozen section examinations were unable to determine whether the tumor was a metastasis or primary lung adenocarcinoma (6,15,18,25). Considering these previous case studies, there is a high likelihood of the misdiagnosis of prostatic adenocarcinoma with lung metastasis as a primary pulmonary neoplasm in clinical practice, and this is considered to be a second pitfall. Copeland et al (29) reported the presence of a tubule-papillary or a carcinoid-like histologic pattern in a pulmonary tumor which was not associated with the histological features of prostate carcinoma (29). Thus, in clinical practice, it is prudent to consider solitary lung metastasis from prostate cancer as a differential diagnosis for patients previously treated for prostate cancer.

However, the surgical resection of isolated lung metastasis from prostate cancer can be justified by its satisfactory outcomes. Pulmonary metastatic lesions which underwent metastasectomies have been closely related to survival in various types of cancer, including colon and uterine cervical cancer (30,31). The number of metastases from prostate cancer
Table I. Clinical data of patients with solitary pulmonary metastasis from prostate cancer obtained from the literature and the present case.

| No. of cases | Authors/(Refs.) | Year of publication | Age, years | Initial characteristics | Initial treatment | Preoperative PSA levels | Lung metastasis characteristics | Solitary lung metastasis treatment | Outcome |
|--------------|-----------------|---------------------|------------|-------------------------|------------------|------------------------|---------------------------------|-----------------------------------|---------|
| 1            | Varkarakis et al (2) | 1974              | Details unknown for 1 case |             |                 | Unknown | Left lower lobe | Orchiectomy                 | Undetectable                  |         |
| 11           | Fabozzi et al (3)  | 1995              | Details unknown for 11 cases |             |                 | Unknown | Right S7, 2 cm | Lung resection              | Undetectable                  |         |
| 1            | Rockey and Graham (4) | 1990              | 83         | Low grade | Radiation therapy | Unknown |                |                                |                                |         |
| 1            | Smith et al (5)   | 1999              | 70         | pT2/GS:4+5 | Radical prostatectomy | Unknown |                |                                |                                |         |
| 1            | Hofland and Bagg (6) | 2000              | 49         | pT3c/GS:4+5 | Radical prostatectomy | 1 | Left lower lobe | Lobectomy                    | Brain metastases            |         |
| 1            | Chao et al (7)    | 2004              | 68         | pT2a/GS:4+5 | Radical prostatectomy | 0.4 | Left lower lobe, 1.2 cm | Wedge resection             | 12-year disease-free follow-up |         |
| 1            | Pruthi et al (8)  | 2007              | 72         | pT2b/GS:3+3 | Radical prostatectomy | 4.1 | Left S8, 2 cm | Endocrine therapy and wedge resection | 3-Year disease-free follow-up |         |
| 1            | Khandani et al (9) | 2009              | 78         | Unknown | Radiation therapy | 8.5 | Left S10, 5 cm | Lobectomy and mediastinal LND | Undetectable                  |         |
| 1            | Boyer and Boyer (10) | 2009              | 65         | pT2/GS:3+3 | Radical prostatectomy | 3 | Left upper lobe, 2.8 cm | Lung resection | Undetectable                  |         |
| 1            | Sakai et al (11)  | 2010              | 74         | Unknown | Endocrine + radiation therapy | 1.24 | Left S8, 2 cm | Wedge resection | 5-Month disease-free follow-up |         |
| 1            | Goto et al (12)   | 2010              | 73         | pT4/GS:4+5 | Neoadjuvant endocrine therapy + pelvic evisceration | Normal range | Right S3, 2 cm | Wedge resection | 10-Month disease-free follow-up |         |
| 1            | Pepe et al (13)   | 2010              | 75         | pT3a/GS:4+3 | Radical prostatectomy | Unknown | Left S6, 2 cm | Segmental resection | 6-Month disease-free follow-up |         |
| 1            | Calais et al (14) | 2014              | 67         | pT1c/GS:4+4 | Endocrine + radiation therapy | 3.5 | Right middle lobe, 4.6 cm | Lobectomy | Undetectable                  |         |
| 1            | Maebayashi et al (15) | 2015              | 50         | cT4/GS:4+5 with NED | Endocrine + radiation therapy | Normal range | Left S5, 3 cm | Lobectomy and mediastinal LND | Died after 2.5 years after metastases were detected |         |
| No. of cases | Authors/(Refs.) | Year of publication | Age, years | Initial characteristics | Initial treatment | Preoperative PSA levels | Lung metastasis characteristics | Solitary lung metastasis treatment | Outcome |
|--------------|-----------------|---------------------|------------|-------------------------|-------------------|------------------------|-------------------------------|-----------------------------|---------|
| 1            | Gago et al (16) | 2016                | 62         | pT3a/GS:7               | Radical prostatectomy | 4.3                    | Left lower lobe             | Wedge resection              | 4-Year disease-free follow-up |
| 1            | Mortier et al (17) | 2016                | 82         | pT3/GS:6                | Radical prostatectomy | 3.32                   | Right S7, 2 cm              | Lobectomy                   | 1-Year disease-free follow-up |
| 1            | Iijima et al (18) | 2017                | 71         | Unknown                 | Radical prostatectomy | 0.521                  | Right S3, 2.2 cm            | Lobectomy and LND            | 2-Year and 3-month disease-free follow-up |
| 1            | Rush et al (19)  | 2017                | 70         | pT4/GS:4+4              | Radical prostatectomy | 2.9                    | Right lower lobe, 4.7 cm   | Segmental resection          | 2-Year disease-free follow-up |
| 1            | Hokamp et al (20) | 2017                | 63         | Unknown                 | Radical + prostatectomy + endocrine + radiation therapy | 1.6                  | Right S1, 1.1 cm            | Lung resection               | Undetectable                 |
| 1            | Boschian et al (21) | 2018                | 69         | pT3a/GS:4+3             | Radical prostatectomy | 0.4                    | Left lower lobe, 1 cm      | Segmental resection and LND | 3-Year disease-free follow-up |
| 1            | Polverali et al (22) | 2019                | 78         | pT2c/GS:4+3             | Radical prostatectomy | 0.33                   | Right S3, 0.7 cm           | Wedge resection + LND        | Undetectable                 |
| 1            | Asano et al (23) | 2019                | 80         | pT3a/GS:4+5             | Radical prostatectomy + endocrine + radiation therapy | 0.33                  | Right S9, 1.1 cm            | Wedge resection              | 1-Year and 7-month disease-free follow-up |
| 1            | Wu et al (24)    | 2020                | 74         | cT4/GS:4+4              | Chemotherapy + endocrine therapy | 3                    | Right S3, 1.8 cm          | Lobectomy                   | 3-Year disease-free follow-up |
| 1            | Present case     | 2020                | 77         | pT2b/GS:3+4             | Radical prostatectomy | 0.412                  | Left S3, 2.1 cm            | Lobectomy and LND            | 1-Year and 4-month disease-free follow-up |
| 1            | Yoshitake et al (25) | 2021                | 83         | Unknown/GS:5            | Radiation therapy    | Normal range             | Right S4                   | Lobectomy and LND            | 5-Year disease-free follow-up |

PSA, prostate-specific antigen; NED, neuroendocrine differentiation; LND, lymph node dissection; GS, Gleason score.
is considered an independent prognostic factor affecting the 5-year cancer-specific survival rate, of which characteristic is the same as other malignancies previously mentioned. The 5-year cancer-specific survival rate for patients with one metastasis is 90%, compared to 32% for those with two or more (32). Surgical resection, particularly for solitary pulmonary lesions, is associated with favorable outcomes in patients with prostate cancer.

In conclusion, as demonstrated in the present study, there are some pitfalls of solitary lung metastasis from prostate cancer leading to misdiagnosis as a primary lung cancer and occasionally they were treated with surgical resection including lobectomy. However, the favorable prognosis in previous case series suggests that surgical resection may be justified.

Acknowledgements

Not applicable.

Funding

No funding was received.
Availability of data and materials

The datasets used and/or data analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

NM and TM wrote the manuscript. NM and TM performed the surgery (a thoracoscopic left upper lobe resection with hilar and mediastinal lymph node dissection). NM, TU, HM, YT, TS, HH and TM determined the treatment plan. AO and KT performed the pathological diagnosis and contributed to the drafting of the pathological findings section of the manuscript. NM and HH confirm the authenticity of all the raw data. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

The present study was approved by the Ethical Committee of Kansai Medical University Hospital (approval no. 2015630). The patient provided written informed consent.

Patient consent for publication

The patient provided consent for the publication of his data and associated images.

Competing interests

The authors declare that they have no competing interests.

References

1. Babendorf L, Schofer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC and Mihatsch MJ: Metastatic patterns of prostate cancer: An autopsy study of 1589 patients. Hum Pathol 31: 578-583, 2000.
2. Varkarakis MJ, Winterberger AR, Gaeta J, Moore RH and Murphy GP: Lung metastases in prostate carcinoma. Clinical significance. Urology 3: 447-452, 1974.
3. Fabozzi SJ, Schellhammer PF and El-Mahdi AM: Pulmonary metastases from prostate cancer. Cancer 75: 2706-2709, 1995.
4. Rockey KE and Graham TE: Prostate adenocarcinoma metastatic to the lung. Postgrad Med 87: 199-205, 1990.
5. Smith CP, Sharma A, Ayala G, Cagle P and Kadmon D: Solitary pulmonary metastasis from prostate cancer. J Urol 162: 2102, 1999.
6. Holland CA and Bagg MD: An isolated pulmonary metastasis in prostate cancer. Mil Med 165: 973-974, 2000.
7. Chao DH, Higgins JP and Brooks JD: Biochemical remission after resection of prostate cancer lung metastasis. Urology 63: 584-585, 2004.
8. Pruthi RS, Hubbard JS, Kourba E and Wallen E: Androgen-independent prostate cancer treated with resection of the solitary metastatic site. Urol Int 79: 371-373, 2007.
9. Khandani AH, Funkhouser WK, Feins R and Socinski MA: Simultaneous FDG PET + Glut1+ lung and FDG PET - Glut1- subcapsular lymph node metastases from prostate cancer. Ann Nucl Med 23: 595-597, 2009.
10. Boyer BP and Boyer MJ: An elusive tumor in a man who has evidence of prostate cancer metastasis. JAPPA 22: 22-25, 2009.
11. Sakai T, Kimura D, Hatamaka R, Yamada Y, Tsushima T, Fukuda I and Kamata Y: Surgical treated pulmonary metastases from prostate cancer: Report of a case. Kyobu Geka 63: 340-343, 2010 (In Japanese).
12. Goto T, Maeshima A, Oyamada Y and Kato R: Solitary pulmonary metastasis from prostate sarcomatoid cancer. World J Surg Oncol 8: 101, 2010.
13. Pepe P, Fraggetta F, Tornabene F, Nicolosi M and Aragona F: Solitary lung metastasis after radical prostatectomy in presence of undetectable PSA. Arch Ital Urol Androl 84: 208-210, 2010.
14. Calais J, Lussato D, Menard J, Kerviler ED, Mangiat-Artus P, Castier Y and Merlet P: Resection of a solitary pulmonary metastasis from prostatic adenocarcinoma misdiagnosed as a B-cell lymphoma: Usefulness of 18F-choline and 18F-FDG PET/CT. J Thorac Oncol 12: 1826-1829, 2014.
15. Maebayashi T, Abe K, Aizawa T, Sakuguchi M, Ishibashi N, Fukushima S, Homma T, Kusumi Y, Matsui T and Kawata N: Solitary pulmonary metastasis from prostate cancer with neuroendocrine differentiation: A case report and a review of relevant cases from the literature. World J Surg Oncol 13: 173-180, 2015.
16. Gago JP, Câmara G, Dionísio J and Opinião A: Pulmonary metastasis as sole manifestation of relapse in previously treated localized prostate cancer: Three exceptional case reports. Pancreasmidsci 10: 645, 2016.
17. Mortier D, Baten E, Vandeuren K and van Renterghem K: The benefit of a surgical resection of a solitary pulmonary metastasis of prostate cancer after radical prostatectomy. Curr Urol 20: 210-212, 2016.
18. Iijima Y, Kinoshita H, Nakajima Y, Akiyama H, Uramoto H and Hirata T: Isolated solitary lung metastasis 12 years after radical prostatectomy for prostate cancer without elevation of the serum prostate-specific antigen level. Jpn J Chest Surg 31: 648-652, 2017 (In Japanese).
19. Rush J, Pai R and Parikh RA: Complete biochemical response after pulmonary metastasectomy in prostate adenocarcinoma. Exp Hematol Oncol 6: 25, 2017.
20. Hokamp NG, Koke C, Linzenich E, Maintz D and Drzega A: Solitary PSMA-positive pulmonary metastasis in biochemical relapse of prostate cancer. Clin Nucl Med 42: 406-407, 2017.
21. Boschian R, Rizzo M, Zandonà L, Trombetta C and Luguirò G: Pulmonary recurrence from prostate cancer and biochemical remission after metastasis directed therapy. A case report. Arch Ital Urol Androl 90: 74-75, 2018.
22. Polverari G, Ceci F, Allen-Auberbach M, Gupta P, Fishbein MC, Reiter RE, Lee J, Hope TA, Carroll RM, Chrnin J and Calais J: Solitary mucinous prostate adenocarcinoma lung metastasis detected by 18F-Ga-PSMA-11 PET/CT. Clin Genitourin Cancer 17: e53-e55, 2019.
23. Asano H, Arakawa S, Kato D, Mori S, Nakada T and Ohtsuka T: A case of single lung metastasis with normal serum PSA level after prostate cancer surgery. Jpn J Chest Surg 33: 66-69, 2019 (In Japanese).
24. Wu LX, Lei L, Zhu YC, Du KQ, Li XF, Chen HF, Wang WX and Xu CW: A prostate cancer patient with isolated lung metastases: A case report. Transl Cancer Res 9: 2064-2068, 2020.
25. Yoshitake H, Oura S, Yamaguchi T and Makimoto S: Solitary lung metastasis of prostate cancer with a long disease-free interval and normal prostate-specific antigen level. Ann Oncol 14: 284-289, 2021.
26. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Masson M, Matveev V, Wiegelt J, Zattoni F, et al.: EUA guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65: 467-474, 2019.
27. Tourinho-Barbosa R, Sprenzi V, Nunes-Silva I, Baghdadi M, Rebecco G, Eiffel SS, Barret E, Rozet F, Galiano M, Cathelineau X and Sanchez-Salas R: Biochemical recurrence after radical prostatectomy: What does it mean? Int Braz J Urol 44: 12-18, 2018.
28. Leibovici D, Spiess PE, Agarwal PK, Tu SM, Pettaway CA, Hitzhusken K, Millikan RE and Pisters P: Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer 109: 198-204, 2007.
29. Copeland JN, Amin BD, Humphrey PA, Tamboli P, Ro JY and Gal AA: The morphologic spectrum of metastatic prostate carcinoma to the lung. Am J Clin Pathol 117: 552-557, 2002.
30. Onatius MW, Petersen RP, Haney JC, Salts L, Park B, Flores R, Rizk N, Bains MS, Dyocco J, D'Amico TA, et al.: Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. Ann Thorac Surg 87: 1684-1688, 2009.
31. Yamamoto K, Yoshikawa H, Shiromizu K, Saito T, Kuzuya K, Tsunematsu R and Kamura T: Pulmonary metastasectomy for uterine cervical cancer: A multivariate analysis. Ann Thorac Surg 77: 1179-1182, 2004.
32. Ost P, Decaestecker K, Lambert B, Fonteyne V, Delrue L, Lumen N, Ameye F and De Meere J: Prognostic factors influencing prostate cancer-specific survival in non-castrated patients with metastatic prostate cancer. Prostate 74: 297-305, 2014.